Eculizumab (Soliris®)

Eculizumab (Soliris®) is approved for reimbursement by the HSE for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) through a Managed Access Process. This funding application process is in place solely to address long-term chronic funding issues for these indications and is not designed to assist hospitals in making acute financial decisions. Therefore, short-term in-patient management remains within the in-patient hospital governance.

For further information relating to the long-term funding of eculizumab for PNH and aHUS, please contact

Applications for individual reimbursement approval will only be considered from consultant haematologists or nephrologists.

The application forms for individual reimbursement approval can be found in the Related Files section below.